Cargando…

Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer

SIMPLE SUMMARY: Recent advances in molecular medicine have indicated G-protein coupled receptors (GPCRs) as possible therapeutic targets in ovarian cancer. The cellular effects of GPCRs are determined by regulator of G protein signaling (RGS) proteins. Especially RGS2 has currently moved into focus...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ihlow, Jana, Monjé, Nanna, Hoffmann, Inga, Bischoff, Philip, Sinn, Bruno Valentin, Schmitt, Wolfgang Daniel, Kunze, Catarina Alisa, Darb-Esfahani, Sylvia, Kulbe, Hagen, Braicu, Elena Ioana, Sehouli, Jalid, Denkert, Carsten, Horst, David, Taube, Eliane Tabea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561967/ https://www.ncbi.nlm.nih.gov/pubmed/36230542 http://dx.doi.org/10.3390/cancers14194620

Ejemplares similares

Prognostic value of regulatory T cells and T helper 17 cells in high grade serous ovarian carcinoma
por: Marchenko, Sofya, et al.
Publicado: (2022)

Increased expression of IDO1 is associated with improved survival and increased number of TILs in patients with high-grade serous ovarian cancer
por: Hoffmann, Inga, et al.
Publicado: (2023)

Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma
por: Darb-Esfahani, Silvia, et al.
Publicado: (2015)

High EVI1 and PARP1 expression as favourable prognostic markers in high-grade serous ovarian carcinoma
por: Jank, Paul, et al.
Publicado: (2023)

Discovery of Prognostic Markers for Early-Stage High-Grade Serous Ovarian Cancer by Maldi-Imaging
por: Kulbe, Hagen, et al.
Publicado: (2020)

Stable expansion of high‐grade serous ovarian cancer organoids requires a low‐Wnt environment
por: Hoffmann, Karen, et al.
Publicado: (2020)

Classification of Molecular Subtypes of High-Grade Serous Ovarian Cancer by MALDI-Imaging
por: Kassuhn, Wanja, et al.
Publicado: (2021)

Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer()
por: Stanske, Mandy, et al.
Publicado: (2018)

Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
por: Ruscito, Ilary, et al.
Publicado: (2018)

High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism
por: Braicu, Elena Ioana, et al.
Publicado: (2017)

Discovery and Validation of Novel Biomarkers for Detection of Epithelial Ovarian Cancer
por: Kulbe, Hagen, et al.
Publicado: (2019)

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer
por: Patel, Jai N., et al.
Publicado: (2018)

Chondroitin Sulfate Disaccharides, a Serum Marker for Primary Serous Epithelial Ovarian Cancer
por: Biskup, Karina, et al.
Publicado: (2021)

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer
por: Woopen, Hannah, et al.
Publicado: (2014)

An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas
por: Noske, Aurelia, et al.
Publicado: (2011)

Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium
por: Glajzer, Jacek, et al.
Publicado: (2022)

Prevalence of human papillomavirus detection in ovarian cancer: a meta-analysis
por: Cherif, Soumia, et al.
Publicado: (2021)

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism
por: Niemi, Riikka Johanna, et al.
Publicado: (2018)

In Silico Analysis Predicts Nuclear Factors NR2F6 and YAP1 as Mesenchymal Subtype-Specific Therapeutic Targets for Ovarian Cancer Patients
por: Kassuhn, Wanja, et al.
Publicado: (2023)

In Situ N-Glycosylation Signatures of Epithelial Ovarian Cancer Tissue as Defined by MALDI Mass Spectrometry Imaging
por: Grzeski, Marta, et al.
Publicado: (2022)

Fertility-Sparing Surgery in Early Epithelial Ovarian Cancer: A Viable Option?
por: Fotopoulou, Christina, et al.
Publicado: (2012)

Neutrophil Granulocytes in Ovarian Cancer - Induction of Epithelial-To-Mesenchymal-Transition and Tumor Cell Migration
por: Mayer, Christine, et al.
Publicado: (2016)

Ambivalent role of pFAK-Y397 in serous ovarian cancer-a study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2014)

Pseudo- or real progression? An ovarian cancer patient under nivolumab: A case report
por: Passler, Mona, et al.
Publicado: (2019)

Neurogenic Inflammation in the Context of Endometriosis—What Do We Know?
por: Velho, Renata Voltolini, et al.
Publicado: (2021)

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
por: Pietzner, Klaus, et al.
Publicado: (2018)

RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers
por: Jones, Wendell D., et al.
Publicado: (2020)

A Novel Two-Lipid Signature Is a Strong and Independent Prognostic Factor in Ovarian Cancer
por: Salminen, Liina, et al.
Publicado: (2021)

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
por: Budczies, Jan, et al.
Publicado: (2012)

Integrated transcriptomic and proteomic analysis identifies protein kinase CK2 as a key signaling node in an inflammatory cytokine network in ovarian cancer cells
por: Kulbe, Hagen, et al.
Publicado: (2016)

Sialic Acid Linkage Analysis Refines the Diagnosis of Ovarian Cancer
por: Dědová, Tereza, et al.
Publicado: (2019)

Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis
por: Baum, Joanna, et al.
Publicado: (2023)

Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium
por: Aust, Stefanie, et al.
Publicado: (2012)

Clinical Significance of Organic Anion Transporting Polypeptide Gene Expression in High-Grade Serous Ovarian Cancer
por: Svoboda, Martin, et al.
Publicado: (2018)

Cell-Free-DNA-Based Copy Number Index Score in Epithelial Ovarian Cancer—Impact for Diagnosis and Treatment Monitoring
por: Braicu, Elena Ioana, et al.
Publicado: (2021)

The Serum Glycome to Discriminate between Early-Stage Epithelial Ovarian Cancer and Benign Ovarian Diseases
por: Biskup, Karina, et al.
Publicado: (2014)

Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study
por: Phelps, David L, et al.
Publicado: (2017)

MicroRNAs that target RGS5
por: Banaei-Esfahani, Amir, et al.
Publicado: (2015)

Prediction of clinical response to drugs in ovarian cancer using the chemotherapy resistance test (CTR-test)
por: Kischkel, Frank Christian, et al.
Publicado: (2017)

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers
por: Braicu, E-I, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h8j651kqmfvjkfe0ljv7vvgnam